(CercleFinance.com) – The specialist in non-alcoholic steatohepatitis Inventiva has published net income for the year 2022 of -54.3 million euros, compared to -49.6 million for 2021, due in particular to an increase in its research and development expenses.
Revenue amounted to €12.2 million, compared to €4.2 million in 2021. Revenues recorded in 2022 are mainly related to Inventiva’s license and collaboration agreement with CTTQ, signed on September 21.
The biopharmaceutical company posted cash and cash equivalents of 86.7 million euros and short-term deposits of one million as of December 31, 2022, compared to 86.6 million and 8.8 million respectively at the end of 2021.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
